Setting A New 52 Week High, Abbott Laboratories (NYSE:ABT) Ends The Day At $81.12

ABT
ABT

Abbott Laboratories (NYSE:ABT)

June 11th, 2019

Amidst falling markets Abbott Laboratories finished Tuesday’s trading session down 0.18%, a ($0.15) decrease to close on $81.12. Despite the drop in price it hit a new 52 week high of $82.00.

ABT outperformed the rest of the Healthcare sector which went down just -0.25% today.

Abbott Laboratories is listed on the S&P 500 index, and was one of 263 stocks that slumped today. Weighted by market cap, ABT represents about 0.57% of the S&P 500.

Analysis results from 20 analysts suggest that Abbott Laboratories might increase somewhat (2.29%), while Finbox has calculated (with low uncertainty) a fair value price of $75.17.

Market Sectors

The market sectors were mixed Tuesday with a majority of the sectors trending up. Consumer Staples saw the biggest increase of the day (0.41%), while the Industrials sector saw the biggest drop (-0.90%). Information Technology has seen the biggest year-to-date gain of 23.75%.

Industrials and Utilities both saw turn-arounds from their five day positive performances with Industrials dropping -0.90%.

Sector Breakdown

  • Consumer Staples, up 0.41%.
  • Consumer Discretionary, up 0.33%.
  • Communication Services, up 0.29%.
  • Real Estate, up 0.18%.
  • Energy, up 0.12%.
  • Information Technology, up 0.02%.
  • Financials, stayed even 0.00%.
  • Materials, down -0.07%.
  • Healthcare, down -0.25%.
  • Utilities, down -0.69%.
  • Industrials, down -0.90%.

Abbott Laboratories Info

Abbott Laboratories discovers, develops, manufactures, and sells health care products worldwide. The company’s Established Pharmaceutical Products segment offers branded generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency; irritable bowel syndrome or biliary spasm; intrahepatic cholestasis or depressive symptom; gynecological disorder; hormone replacement therapy; dyslipidemia; hypertension; hypothyroidism; Ménière’s disease and vestibular vertigo; pain, fever, and inflammation; migraine; and anti-infective clarithromycin, as well as provides influenza vaccines and products that regulate physiological rhythm of the colon. Its Diagnostic Products segment offers core laboratory systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automates the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detects and measures infectious agents; cartridges for blood analysis; rapid diagnostics systems for infectious diseases; molecular point-of-care care testing for HIV, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test systems, as well as remote patient monitoring and consumer self-test systems; and informatics and automation solutions for use in laboratories. The company’s Nutritional Products segment provides pediatric and adult nutritional products. Its Cardiovascular and Neuromodulation Products segment offers rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases, as well as neuromodulation devices for the management of chronic pain and movement disorders. The company also provides glucose and blood glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes. The company was founded in 1888 and is headquartered in Abbott Park, Illinois.

All amounts in USD unless otherwise indicated

ABT daily update
ABT daily update

Media Gazelle Inc (MG), a Nevada Corporation, owns and operates the online brand US Tribune News. MG does not offer financial advise, and is not a registered broker/dealer/analyst/adviser, holds no investment licenses, and may not sell, offer to sell or offer to buy any security. MG’s market updates, news are not a solicitation or recommendation to buy, sell or hold securities. MG shall not be held liable for any investment losses you may incur by using the information provided, this includes you trading the stocks mentioned on our sites. We recommend you talk to a financial adviser before trading any securities or taking any action based upon information on this site. MG does not guarantee the accuracy of the article.

This site uses Akismet to reduce spam. Learn how your comment data is processed.